Travere Therapeutics, Inc.
TVTX
$28.27
$0.471.67%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 104.53% | 146.90% | 81.88% | 69.70% | 33.17% |
| Total Depreciation and Amortization | 50.00% | 40.48% | 35.49% | 29.57% | 27.43% |
| Total Amortization of Deferred Charges | -4.93% | -- | -- | -- | 0.41% |
| Total Other Non-Cash Items | -535.65% | 30.14% | -88.38% | -1.97% | 138.84% |
| Change in Net Operating Assets | 611.61% | -454.05% | 90.72% | -704.24% | 4.22% |
| Cash from Operations | 269.87% | 133.68% | 112.38% | 64.54% | 49.31% |
| Capital Expenditure | 357.32% | -- | -186.59% | -- | -87.25% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -30.88% | 88.03% | -82.28% | -60.64% | -356.95% |
| Cash from Investing | -30.54% | 87.73% | -83.05% | -60.64% | -373.80% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -80.52% | 616.29% | 53.02% | -- | 15,279.30% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00% | 0.00% | 0.00% | 0.00% | 33.04% |
| Cash from Financing | -80.82% | -142,141.30% | 88.62% | 808.19% | 112,092.74% |
| Foreign Exchange rate Adjustments | 57.16% | -54.30% | 1,888.07% | 287.03% | -178.31% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -180.88% | 768.77% | 220.96% | 122.53% | 125.71% |